our Premium Content: News alerts, weekly reports and conference planners

GENE:

MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)

News alerts, weekly reports and conference planners

13d

Genomic and immune landscape of recurrent and/or metastatic squamous cell carcinoma of the head and neck progressing on anti-PD1 treatment. (PubMed, Cancer Immunol Res)

Additionally, high B2M expression correlated with greater T cell infiltration and improved survival following anti-PD1 therapy. Tumor cell B2M expression was independent of TMB and PD-L1 expression, suggesting that B2M expression could serve as an additional biomarker for anti-PD1 response.

13 days ago

Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • B2M (Beta-2-microglobulin) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)

PD-L1 expression

23d

Circ_0001839 modulates the oncogenic MYCL rs1038259890 (p.G83S) mutation to promote B[a]P-induced malignant transformation in 16HBE cells. (PubMed, J Hazard Mater)

Functional integration analysis demonstrated that circ_0001839 depletion potentiates the oncogenic effects of the MYCL p.Gly83Ser mutation, accelerating B[a]P-induced malignant transformation through dysregulated transcriptional networks. This study explores the regulatory function of circRNAs on gene mutations during chemicals-induced carcinogenesis, offering innovative insights into the toxicological effects and biological pathways of B[a]P on human health.

23 days ago

Journal

MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)

Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. (PubMed, JCO Precis Oncol)

Our study reveals the preliminary molecular landscape of Chinese pediatric sarcomas, indicating that molecular changes may represent different therapeutic responses and pathologic characteristics may correlate with molecular characteristics, suggesting the need for panel sequencing for pediatric sarcoma.

1 month ago

Journal

TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)

TP53 mutation • KRAS mutation • NRAS mutation

2ms

A MYC Family Switch: L-MYC Drives and Maintains Neuroendocrine Lineage Programs in Prostate Cancer. (PubMed, bioRxiv)

We further identify ASCL1 and INSM1 as upstream regulators of MYCL, establishing a conserved neuroendocrine transcriptional axis. Together, these findings define MYCL as a lineage-specific regulator that drives neuroendocrine identity and plasticity in advanced prostate cancer.

2 months ago

Journal

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)

MYCL expression

3ms

Single-Cell Analysis of L-Myc Expressing Neural Stem Cells and Their Extracellular Vesicles Revealed Distinct Progenitor Populations With Neurogenic Potential. (PubMed, J Extracell Biol)

These LMNSC-EVs (collected from undifferentiated LMNSCs) demonstrated neuroprotective effects in a brain organoid model of methotrexate-induced toxicity when added to corresponding LMNSC01- or LMNSC02-derived brain organoids. LMNSC01- and LMNSC02-derived EVs restored neuronal and astrocytic populations but failed to rescue OPCs. These findings demonstrate the therapeutic potential of LMNSC-derived EVs to counter chemotherapy-induced neurotoxicity by preserving neurones and astrocytes, while highlighting the need for repeated or complementary interventions to restore oligodendrocyte populations.

3 months ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • CD9 (CD9 Molecule) • CD81 (CD81 Molecule)

methotrexate

5ms

The Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions. (PubMed, Front Biosci (Landmark Ed))

While direct targeting of MYC has proven challenging, recent advances in therapeutic strategies, including MYC-MYC-associated factor X (MAX) dimerization inhibitors, bromodomain and extra terminal domain (BET) and cyclin dependent kinase (CDK) inhibitors, synthetic lethality approaches, and epigenetic modulators, have shown promising results in preclinical and early clinical settings. This review discusses MYC's comprehensive impact on TIME and examines the promising therapeutic strategies of MYC inhibition in enhancing the effectiveness of immunotherapies, supported by recent preclinical and clinical findings.

5 months ago

Review • Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • MAX (MYC Associated Factor X)

5ms

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (clinicaltrials.gov)

P=N/A, N=50000, Recruiting, Massive Bio, Inc. | Trial completion date: Jun 2027 --> Jun 2040 | Trial primary completion date: Dec 2026 --> Dec 2038

5 months ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • STK11 (Serine/threonine kinase 11) • NPM1 (Nucleophosmin 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • RB1 (RB Transcriptional Corepressor 1) • CLDN18 (Claudin 18) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • NRG1 (Neuregulin 1) • POLE (DNA Polymerase Epsilon) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PD-1 (Programmed cell death 1) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • KDR (Kinase insert domain receptor) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • VEGFA (Vascular endothelial growth factor A) • BCL6 (B-cell CLL/lymphoma 6) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • PTCH1 (Patched 1) • FGFR4 (Fibroblast growth factor receptor 4) • MSH6 (MutS homolog 6) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • WT1 (WT1 Transcription Factor) • ATRX (ATRX Chromatin Remodeler) • BRCA (Breast cancer early onset) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • TSC2 (TSC complex subunit 2) • CHEK2 (Checkpoint kinase 2) • PD-L2 (Programmed Cell Death 1 Ligand 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • JAK1 (Janus Kinase 1) • FANCA (FA Complementation Group A) • TSC1 (TSC complex subunit 1) • MDM4 (The mouse double minute 4) • POLD1 (DNA Polymerase Delta 1) • CDK6 (Cyclin-dependent kinase 6) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • AURKA (Aurora kinase A) • JAK3 (Janus Kinase 3) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • CHEK1 (Checkpoint kinase 1) • GATA6 (GATA Binding Protein 6) • MSH3 (MutS Homolog 3) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • GNAS (GNAS Complex Locus) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3) • CSF1R (Colony stimulating factor 1 receptor) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • HDAC1 (Histone Deacetylase 1) • PRDM1 (PR/SET Domain 1) • ZNF217 (Zinc Finger Protein 217) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • GATA3 (GATA binding protein 3) • PARP2 (Poly(ADP-Ribose) Polymerase 2) • PARP3 (Poly(ADP-Ribose) Polymerase Family Member 3) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • ACVR1B (Activin A Receptor Type 1B) • ZNF703 (Zinc Finger Protein 703)

HER-2 mutation • AKT1 mutation

6ms

Protein arginine methyltransferase 5 sustains Tip60-EP400 complex via SRSF1 in Merkel cell carcinoma. (PubMed, Life Sci Alliance)

PRMT5 inhibition disrupts this recruitment, leading to widespread splicing defects, including exon skipping and intron retention. These results provide new insights into PRMT5's role in splicing regulation and may have broader implications for targeting splicing dysregulation in MYC-driven cancers.

6 months ago

Journal

TP53 (Tumor protein P53) • MTAP (Methylthioadenosine Phosphorylase) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • PRMT5 (Protein Arginine Methyltransferase 5) • EP400 (E1A Binding Protein P400)

TP53 wild-type • MTAP deletion

7ms

Genetic mutations in recurrent and/or metastatic nasopharyngeal carcinoma - an analysis of the Japanese national genomic profiling database. (PubMed, Otolaryngol Pol)

The hazard ratios for cases with these mutations were 0.0122 (95% CI, 1.58×10-4-0.936, p = 0.046) for TP53, 1847.0 (95% CI, 4.619-7.386×105, p = 0.014) for DNMT3A, 126.7 (95% CI, 1.262-12720, p = 0.039) for BRCA2, 197.9 (95% CI, 2.844-13770, p = 0.015) for ALK, 34.22 (95% CI, 1.256-932.7, p = 0.036) for SPEN, and 6.445×10-4 (95% CI, 2.913×10-6-0.143, p = 7.6×10-3) for MYCL. This study identified genetic mutations in recurrent and/or metastatic NPC. Even in advanced cases, prognosis-related mutations were identified, underscoring the importance of cancer genomic profiling tests.

7 months ago

Journal • BRCA Biomarker

ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • DNMT3A (DNA methyltransferase 1) • NOTCH1 (Notch 1) • MTAP (Methylthioadenosine Phosphorylase) • KMT2A (Lysine Methyltransferase 2A) • KMT2D (Lysine Methyltransferase 2D) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • TSC1 (TSC complex subunit 1) • EP300 (E1A binding protein p300) • GNAS (GNAS Complex Locus) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)

TP53 mutation

FoundationOne® CDx • FoundationOne® Liquid CDx

10ms

Amplification of extrachromosomal MYC paralogs shapes immunosuppressive tumor microenvironment in small cell lung cancer. (PubMed, Clin Cancer Res)

Extrachromosomal amplification of MYC-paralogs shapes suppressive TIME, identifying potential subgroup of immunotherapy resistant patients.

10 months ago

Journal • IO biomarker

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • FOXP3 (Forkhead Box P3) • MKI67 (Marker of proliferation Ki-67)

10ms

In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer. (PubMed, Sci Adv)

Data from the IMpower133 clinical trial revealed ~6% of patients with extensive-stage SCLC exhibit KEAP1 genetic alterations, with activation of a KEAP1/NRF2 transcriptional signature associated with reduced survival upon chemotherapy treatment. While roles for KEAP1/NRF2 have been unappreciated in SCLC, our genetic screens revealed KEAP1 loss as a driver of chemoresistance, while patient genomic analyses demonstrate clinical importance.

10 months ago

Preclinical • Journal

KEAP1 (Kelch Like ECH Associated Protein 1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)

11ms

BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov)

P1, N=117, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Jan 2026

11 months ago

Trial completion date

HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)

FGFR3 mutation • CDKN2A deletion • FGFR fusion

Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)